Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
buparlisib + erlotinib
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Buparlisib + erlotinib is a combination therapy investigated for the treatment of advanced non-small cell lung cancer (NSCLC). Buparlisib (BKM120) is an oral, pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor that targets all four catalytic isoforms (p110α, p110β, p110δ, and p110γ). Erlotinib is an oral small molecule tyrosine kinase inhibitor that specifically targets the epidermal growth factor receptor (EGFR). The combination was evaluated by SCRI Development Innovations, LLC (Sarah Cannon Research Institute) in Phase II clinical trials to address resistance to EGFR-targeted therapies. The therapeutic rationale is that buparlisib can down-modulate the PI3K-Akt signaling pathway, which is often upregulated as a resistance mechanism in EGFR-mutant lung cancers, thereby restoring or enhancing the anti-tumor activity of erlotinib.
- Other names
- BKM120 + erlotinibbuparlisib + erlotinib
02
Targets
EGFR (Epidermal growth factor receptor)PIK3CA (Phosphoinositide 3-kinase alpha)PIK3CB (Phosphatidylinositol 3-kinase beta subunit)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)PIK3CD (Phosphatidylinositol 3-kinase delta)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on buparlisib + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on buparlisib + erlotinib.